UAB COVID Drug Potent for Gilead without “Orphan” Status

Dr. Richard Whitley, UAB distinguished professor, Gilead board member A University of Alabama at Birmingham-researched drug with potential for treating COVID-19 recently received FDA approval as a rare disease treatment, a distinction that looked like a windfall for its developer, California-based Gilead Sciences. But the company suddenly announced it was turning…

Thank you for reading!

To continue reading this article you must be registered and logged into this site. If you already have an account please login now, otherwise you can click here to register for new account. Registration is FREE.

Login       Register

The latest Alabama business news delivered to your inbox